Edesa Biotech Inc.
| NASDAQ: EDSA | Healthcare / Biotechnology / Canada |
| 3.31 | +0.1599 | +5.08% | Vol 10.40K | 1Y Perf 253.94% |
| Nov 29th, 2023 15:49 DELAYED |
| BID | 3.28 | ASK | 3.34 | ||
| Open | 3.25 | Previous Close | 3.15 | ||
| Pre-Market | - | After-Market | 3.42 | ||
| - - | 0.11 3.25% |
| Target Price | 13.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 292.75 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | ★★ 46.79 | |
| Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | ★★ 46.02 | |
| Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 4.94 | Earnings Rating | — | |
| Market Cap | 9.97M | Earnings Date | 15th Dec 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.32 | |
| Beta | 0.50 |
Today's Price Range 3.233.35 | 52W Range 2.4619.67 | 5 Year PE Ratio Range -5.50-1.40 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 4.67% | ||
| 1 Month | 5.08% | ||
| 3 Months | 293.11% | ||
| 6 Months | 267.82% | ||
| 1 Year | 253.94% | ||
| 3 Years | -36.50% | ||
| 5 Years | -50.74% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -51.86 | |||
ROE last 12 Months | -171.60 | |||
ROA (5Y Avg) | -20.06 | |||
ROA last 12 Months | -146.66 | |||
ROC (5Y Avg) | -75.54 | |||
ROC last 12 Months | -132.66 | |||
Return on invested Capital Q | -26.78 | |||
Return on invested Capital Y | -155.86 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.40 | ||||
| 5.23 | ||||
| 470.04 | ||||
| - | ||||
| -5.40 | ||||
| -0.74 | ||||
| 6.91 | ||||
| 0.49 | ||||
| 42.09M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.90 | ||||
| 4.20 | ||||
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| Leverage Ratio | 1.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -362.80 | ||||
| -2 346 000.00 | ||||
| -2 322 230.00 | ||||
| -1 825.60 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| -43.85 | ||||
| -9.56 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | -1.19 | -0.70 | 41.18 |
| Q02 2023 | -1.19 | -0.84 | 29.41 |
| Q01 2023 | -1.33 | -0.91 | 31.58 |
| Q04 2022 | -2.80 | -0.07 | 97.50 |
| Q03 2022 | -2.52 | -2.59 | -2.78 |
| Q02 2022 | -0.37 | -0.33 | 10.81 |
| Q01 2022 | -0.40 | -0.33 | 17.50 |
| Q04 2021 | -0.37 | -0.27 | 27.03 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 15th Dec 2023 |
| Estimated EPS Next Report | -0.70 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 10.40K |
| Shares Outstanding | 3.01K |
| Shares Float | 2.01M |
| Trades Count | 136 |
| Dollar Volume | 33.98K |
| Avg. Volume | 60.01K |
| Avg. Weekly Volume | 22.42K |
| Avg. Monthly Volume | 23.54K |
| Avg. Quarterly Volume | 134.06K |
Edesa Biotech Inc. (NASDAQ: EDSA) stock closed at 3.31 per share at the end of the most recent trading day (a 5.08% change compared to the prior day closing price) with a volume of 10.40K shares and market capitalization of 9.97M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 10 people. Edesa Biotech Inc. CEO is Pardeep Nijhawan.
The one-year performance of Edesa Biotech Inc. stock is 253.94%, while year-to-date (YTD) performance is 53.24%. EDSA stock has a five-year performance of -50.74%. Its 52-week range is between 2.4603 and 19.67, which gives EDSA stock a 52-week price range ratio of 4.94%
Edesa Biotech Inc. currently has a PE ratio of -2.40, a price-to-book (PB) ratio of 5.23, a price-to-sale (PS) ratio of 470.04, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -146.66%, a ROC of -132.66% and a ROE of -171.60%. The company’s profit margin is -%, its EBITDA margin is -2 322 230.00%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Edesa Biotech Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.70 for the next earnings report. Edesa Biotech Inc.’s next earnings report date is 15th Dec 2023.
The consensus rating of Wall Street analysts for Edesa Biotech Inc. is Strong Buy (1), with a target price of $13, which is +292.75% compared to the current price. The earnings rating for Edesa Biotech Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Edesa Biotech Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Edesa Biotech Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 22.47, ATR14 : 0.37, CCI20 : 27.60, Chaikin Money Flow : -0.38, MACD : 0.12, Money Flow Index : 36.80, ROC : 0.64, RSI : 54.62, STOCH (14,3) : 61.40, STOCH RSI : 0.73, UO : 32.67, Williams %R : -38.60), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Edesa Biotech Inc. in the last 12-months were: Peter Van der Velden (Sold 297 474 shares of value $787 716 )
Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side-effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.
CEO: Pardeep Nijhawan
Telephone: +1 905 475-1234
Address: 100 Spy Court, Markham L3R 5H6, ON, CA
Number of employees: 10
